Edmund Lee, Ph.D..

Edmund Lee, Ph.D.

Edmund is Vice President, Translational Medicine at Regulus Therapeutics. Prior to joining Regulus, he was with Hoffmann-La Roche and Millennium Pharmaceuticals (now Takeda Oncology), where he participated in the discovery of the proteosome inhibitor ixazomib (MLN9708) for the treatment of multiple myeloma. Edmund has led numerous discovery and translational research programs, including most recently the first anti-miR-17 oligonucleotide (RGLS4326), as well as the next-generation anti-miR-17 (RGLS8429) for the potential treatment of ADPKD. Edmund received his B.Sc. (Honors) in biochemistry from Queen’s University in Ontario Canada, his Ph.D. in cell and molecular biology from the University of Notre Dame, and completed his postdoctoral training at the Fred Hutchinson Cancer Research Center.